Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients.

ABSTRACT:

Background

Little is known on factors predicting sunitinib toxicity. Recently, the condition of low muscle mass, named sarcopenia, was identified as a significant predictor of toxicity in metastatic renal cell cancer (mRCC) patients treated with sorafenib. We investigated whether sarcopenia could predict early dose-limiting toxicities (DLTs) occurrence in mRCC patients treated with sunitinib.

Methods

Consecutive mRCC patients treated with sunitinib were retrospectively reviewed. A DLT was defined as any toxicity leading to dose reduction or treatment discontinuation. Body composition was evaluated using CT scan obtained within 1 month before treatment initiation.

Results

Among 61 patients eligible for analysis, 52.5% were sarcopenic and 32.8% had both sarcopenia and a

SUBMITTER: Huillard O 

PROVIDER: S-EPMC3619075 | biostudies-literature | 2013 Mar

REPOSITORIES: biostudies-literature